Patient Engagement

Separate study says 45 percent may be a low estimate and number could be closer to 65 percent.

Mylan said Monday it will offer a generic version of the life-saving allergy treatment following weeks of criticism over price hike.

Programs substantially cut the risk of dying from another cardiac problem, improve quality of life and lower costs; less than one-third of patients whose conditions qualify for the rehab actually participate.

Mylan CEO Heather Bresch calls new option "an extraordinary commercial response" following rising backlash from public, lawmakers on price hike.

"Adverse drug events" drive up health care costs annually by about $3.5 billion, add about three days to the average stay, DHHS says.

Legislation also would require the nation's first minimum nurse-to patient staffing ratios in observation care units.

Intermountain Healthcare study conducted at 27 team-based medical practices and 75 traditional practices revealed that delivering integrated mental and physical healthcare in team-based primary care settings yields better results for patients and also reduces the rates healthcare utilization and lowers cost.

SPOT facility, professionals offer safe place to ride out high, seek new start for treatment.

Responding to pressure from lawmakers and the public, Mylan Pharmaceutical is expanding existing programs to make its EpiPen emergency allergy treatments more affordable.

State officials do not quibble about where Georgia ranks and note that the numbers have risen since 2010. And they vow to do something about it.